Mahle Metal Leve SA
BOVESPA:LEVE3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Mahle Metal Leve SA
BOVESPA:LEVE3
|
BR |
|
Vivani Medical Inc
NASDAQ:VANI
|
US |
|
C
|
CircuTech International Holdings Ltd
HKEX:8051
|
HK |
|
R
|
Resmed Inc
ASX:RMD
|
US |
Wall Street
Price Targets
LEVE3 Price Targets Summary
Mahle Metal Leve SA
According to Wall Street analysts, the average 1-year price target for LEVE3 is 39.27 BRL with a low forecast of 34.34 BRL and a high forecast of 45.15 BRL.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is LEVE3's stock price target?
Price Target
39.27
BRL
According to Wall Street analysts, the average 1-year price target for LEVE3 is 39.27 BRL with a low forecast of 34.34 BRL and a high forecast of 45.15 BRL.
What is Mahle Metal Leve SA's Revenue forecast?
Projected CAGR
7%
For the last 14 years the compound annual growth rate for Mahle Metal Leve SA's revenue is 7%. The projected CAGR for the next 2 years is 7%.
What is Mahle Metal Leve SA's Operating Income forecast?
Projected CAGR
8%
For the last 14 years the compound annual growth rate for Mahle Metal Leve SA's operating income is 9%. The projected CAGR for the next 2 years is 8%.
What is Mahle Metal Leve SA's Net Income forecast?
Projected CAGR
9%
For the last 14 years the compound annual growth rate for Mahle Metal Leve SA's net income is 9%. The projected CAGR for the next 2 years is 9%.
